Lupin - Cost Optimization Leads Earnings Upgrade In Q3: Prabhudas Lilladher  
Tablets fall into a collection bin inside the Lupin pharmaceutical plant in Salcette, Goa. (Photographer: Dhiraj Singh/Bloomberg)

Lupin - Cost Optimization Leads Earnings Upgrade In Q3: Prabhudas Lilladher  

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Prabhudas Lilladher Report

We increase our earnings estimate of Lupin Ltd. by 8%/4%/6% for FY21/22/23E on back of lower research and development spend guidance of 9% of sales (versus earlier 10%) and cost optimization towards U.S. branded business.

Q3 FY21 Ebitdam was higher than our estimate as R&D spend declined 19% YoY and 9% QoQ with favorable business mix.

The company’s margin has been lower (compared to peers of 18-20%) due to cost escalation in recent past, regulatory issues and lack of key products launch.

Click on the attachment to read the full report:

Prabhudas Lilladher Lupin Q3FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.